Vaccines
Please check out the biopharma industry’s COVID-19 stories that are trending for June 22, 2021.
Though the world is reopening, this pandemic is not over. Moderna continues expanding production to answer the call globally.
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
The study also found the vaccine was 100% effective at preventing moderate and severe disease.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
Half of these doses will be shared by the U.S., while the U.K. has committed another 100 million shots.
The Pennsylvania-based eye disease company had to change its application from an Emergency Use Authorization to a full BLA approval.
Pfizer says it expects the U.S. CDC’s ACI to meet in October to recommend the appropriate and safe use of pneumococcal vaccines, including PREVNAR 20, in adults.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 8, 2021.
PRESS RELEASES